EUCOPE Blog

Showing all entries tagged with »rare diseases«

October 12, 2022

What is Needed to Reinforce Biopharmaceutical Innovation in Europe?

The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed to change that but in reality, is discouraging innovation and competitiveness…. read more


April 27, 2022

Five Priorities for a Successful EU HTA Procedure

With the European Union’s new Regulation (EU) 2021/2282 on health technology assessment, the evaluation of certain new therapies will now be performed jointly at the European level for the first time. The aims are to speed up access to new… read more


February 26, 2021

HERA: closer coordination in the EU against COVID-19

On 27 January, the European Commission launched the consultation on the European Health Emergency Preparedness and Response Authority, HERA for short. The consultation, which main aim is to issue a legislative proposal on the new authority by the end of… read more


May 15, 2020

ECRD 2020: OMPs Development in a post-COVID-19 World

The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds.  Bringing the perspective of OMP focused small… read more


February 27, 2020

Rare Disease Day: Celebrating an empowered community

On Rare Diseases Day, EUCOPE is delighted to host an interview with Laurence Woollard, patient expert and rare disease advocate, to discuss with him the importance of an engaged community and the opportunities and challenges new treatments can bring. Hi… read more